Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has priced a registered direct offering of 3.5 million equity units at $2 apiece, giving the transaction a $7 million value.

Each unit consists of one share of Cancer Genetics' common stock and one warrant to buy an additional share at an exercise price of $2.35. The warrants are exercisable six months after the date of issuance, and expire 18 months after issuance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.